Changing demography of prostate cancer in Asia

European Journal of Cancer

Volumn 41, Issue 6, 2005, Pages 834-845

  Sim, Hong Gee ^a   Cheng, Christopher W S ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Aetiology; Asian; Association; Epidemiology; Incidence rate; Mortality rate; Prostate cancer; Risk factor

Indexed keywords

ANDROGEN RECEPTOR; ISOFLAVONOID; POLYPHENOL;

AGE DISTRIBUTION; ANDROGEN METABOLISM; ASIA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CHINA; DEMOGRAPHY; DIET; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; GENETIC POLYMORPHISM; HUMAN; JAPAN; KOREA; PHILIPPINES; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGAPORE; THAILAND;

EID: 16344368667     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.12.033     Document Type: Article

References (115)

1. J. Ferlay, F. Bray, and P. Pisani GLOBOSCAN 2000: cancer incidence, mortality and prevalence worldwide 2001 International Agency for Research on Cancer Lyon
2. A.L. Potosky, B.A. Miller, and P.C. Albertsen The role of increasing detection in the rising incidence of prostate cancer JAMA 273 1995 548 552
3. F.A. Majeed, and N.A. Burgess Trends in death rates and registration rates for prostate cancer in England and Wales BJU 73 1994 377 381
4. E. Chirpaz, M. Colonna, and F. Menegoz Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996 Int J Cancer 97 3 2002 372 376
5. A.W. Hsing, L. Tsao, and S.S. Devesa International trends and patterns of prostate cancer incidence and mortality Int J Cancer 85 2000 60 67
6. C. Muir J. Waterhouse T. Mack Cancer incidence in five continents, vol. V. IARC Scientific Publications, 88 1987 International Agency for Research in Cancer Lyon
7. D.M. Parkin C.S. Muir S.L. Whelan Cancer incidence in five continents, vol. VI. IARC Scientific Publications, 120 1992 International Agency for Research in Cancer Lyon
8. D.M. Parkin S.L. Whelan J. Ferlay Cancer incidence in five continents, vol. VII. IARC Scientific Publications, 143 1997 International Agency for Research in Cancer Lyon
9. D.M. Parkin S.L. Whelan J. Ferlay Cancer incidence in five continents, vol. VIII. IARC Scientific Publications, 155 2002 International Agency for Research in Cancer Lyon
10. World Health Organisation. Mortality Data Bank, June 2004. Available from: http://www-depdb.iarc.fr/who/menu.htm
11. A.. Shibata, J. Ma, and A.S. Whittemore Prostate cancer incidence and mortality in the United States and the United Kingdom J Natl Cancer Inst 90 1998 1230 1231
12. H.H. Tan, E. Gan, and I. Rekhraj Use of prostate-specific antigen and transrectal ultrasound in the diagnosis of prostate cancer - a local experience Ann Acad Med Singapore 24 1995 550 556
13. B.T.H. Wong, M.B.W. Que, and P.S. Szeto Establishing a 'reference range' of serum prostate-specific antigen for Asians Asian J Surg 22 1999 240 244
14. L.G. Ng, S. Yip, and P.H. Tan Improved detection rate of prostate cancer using the 10-core biopsy strategy in Singapore Asian J Surg 25 3 2002 238 243
15. C.A. Heinlein, and C. Chang Androgen receptor in prostate cancer Endocr Rev 25 2 2004 276 308
16. A. Edwards, H.A. Hammond, and L. Jin Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups Genomics 12 1992 241 253
17. R.A. Irvine, M.C. Yu, and R.K. Ross The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer Cancer Res 55 9 1995 1937 1940
18. E. Giovannucci, M.J. Stampfer, and K. Krithivas The CAG repeat within the androgen receptor gene and its relationship to prostate cancer Proc Natl Acad Sci 94 1997 3320 3323
19. O. Sartor, Q. Zheng, and J.A. Eastham Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer Urology 53 2 1999 378 380
20. A.W. Hsing, Y.T. Gao, and G. Wu Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case control study in China Cancer Res 60 18 2000 5111 5116
21. J.H. Liu, H.W. Li, and M. Tong Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84 5 2004 364 368
22. B. Jin, J. Beilin, and J. Zajac Androgen receptor gene polymorphism and prostate zonal volumes in Australian and Chinese men J Androl 21 1 2000 91 98
23. E.A. Platz, E.B. Rimm, and W.C. Willett Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals J Natl Cancer Inst 92 24 2000 2009 2017
24. T. Habuchi, T. Suzuki, and R. Sasaki Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population Cancer Res 60 2 2000 305 308
25. S.P. Huang, Y.H. Chou, and W.S. Wayne Chang Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population Cancer Lett 207 1 2004 69 77
26. C. Ntais, A. Polycarpou, and J.P. Ioannidis Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis Cancer Epidemiol Biomarkers Prev 12 12 2003 1395 1402
27. M.T. Tayeb, C. Clark, and N.E. Haites CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia Br J Cancer 88 6 2003 928 932
28. K. Suzuki, H. Matsui, and N. Ohtake Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population Int J Urol 10 5 2003 261 266
29. M.B. Cheteri, J.L. Stanford, and D.M. Friedrichsen Vitamin D receptor gene polymorphisms and prostate cancer risk Prostate 59 4 2004 409 418
30. Y. Yang, S. Wang, and Z. Ye Association of single nucleotide polymorphism of vitamin D receptor gene start codon and the susceptibility to prostate cancer in the Han nationality in Hubei area Zhonghua Nan Ke Xue 10 6 2004 411 414
31. J.H. Liu, H.W. Li, and J.Q. Wang Vitamin D receptor gene BsmI polymorphism and the susceptibility to prostate cancer in northern Chinese Han population Zhonghua Nan Ke Xue 9 6 2003 413 416
32. A.P. Chokkalingam, K.A. McGlynn, and Y.T. Gao Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China Cancer Res 61 11 2001 4333 4336
33. R.M. Lunn, D.A. Bell, and J.L. Mohler Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2) Carcinogenesis 20 9 1999 1727 1731
34. A. Gsur, G. Bernhofer, and S. Hinteregger A polymorphism in the CYP17 gene is associated with prostate cancer risk Int J Cancer 87 3 2000 434 437
35. C.A. Haiman, M.J. Stampfer, and E. Giovannucci The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer Cancer Epidemiol Biomarkers Prev 10 7 2001 743 748
36. Y. Yamada, M. Watanabe, and M. Murata Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population Int J Cancer 92 5 2001 683 686
37. T. Habuchi, Z. Liqing, and T. Suzuki Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect Cancer Res 60 20 2000 5710 5713
38. M.P. Madigan, Y.T. Gao, and J. Deng CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China Int J Cancer 107 2 2003 271 275
39. C.C. Lin, H.C. Wu, and W.C. Chen CYP17 gene promoter allelic variant is not associated with prostate cancer Urol Oncol 21 4 2003 262 265
40. R.K. Nam, A. Toi, and D. Vesprini V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression Urology 57 1 2001 199 204
41. A.W. Hsing, C. Chen, and A.P. Chokkalingam Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study Cancer Epidemiol Biomarkers Prev 10 10 2001 1077 1082
42. P.G. Febbo, P.W. Kantoff, and E.A. Platz The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer Cancer Res 59 23 1999 5878 5881
43. Coffey DS. Physiological control of prostate growth. An overview. In: Prostate cancer. UICC technical report series, vol. 48. Geneva: International Union Against Cancer; 1999
44. C. Huggins, and C.V. Hodges Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, 1941 J Urol 168 1 2002 9 12
45. R. Ross, L. Bernstein, and H. Judd Serum testosterone levels in healthy young black and white men J Natl Cancer Inst 76 1 1986 45 48
46. R.K. Ross, L. Bernstein, and R.A. Lobo 5-alpha-Reductase activity and risk of prostate cancer among Japanese and US white and black males Lancet 339 8798 1992 887 889
47. A.H. Wu, A.S. Whittemore, and L.N. Kolonel Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada Cancer Epidemiol Biomarkers Prev 4 7 1995 735 741
48. P.H. Gann, C.H. Hennekens, and J. Ma Prospective study of sex hormone levels and risks of prostate cancer J Natl Cancer Inst 88 16 1996 1118 1126
49. W. Demark-Wahnefried, S.M. Lesko, and M.R. Conaway Serum androgens: associations with prostate cancer risk and hair patterning J Androl 18 5 1997 495 500
50. T. Shaneyfelt, R. Husein, and G. Bubley Hormonal predictors of prostate cancer: a meta-analysis J Clin Oncol 18 4 2000 847 853
51. L.J. Vatten, G. Ursin, and R.K. Ross Androgens in serum and the risk of prostate cancer: a nested control study from the Janus serum bank in Norway Cancer Epidemiol Biomarkers Prev 6 1997 967 969
52. R. Heikkila, K. Aho, and M. Heliovaara Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study Cancer 86 2 1999 312 315
53. B.A. Mohr, H.A. Feldman, and L.A. Kalish Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts male aging study Urology 57 5 2001 930 935
54. C. Chen, N.S. Weiss, and F.Z. Stanczyk Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinol efficacy trial Cancer Epidemiol Biomarkers Prev 12 12 2003 1410 1416
55. J.F. Dorgan, D. Albanes, and J. Virtamo Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland Cancer Epidemiol Biomarkers Prev 7 12 1998 1069 1074
56. P. Cohen, D.M. Peehl, and G. Lamson Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells J Clin Endocrinol Metab 73 1991 401 407
57. M. Iwamura, P.M. Sluss, and J.B. Casamento Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines Prostate 22 1993 243 252
58. M. Pollak, W. Beamer, and J.C. Zhang Insulin-like growth factors and prostate cancer Cancer Metastasis Rev 17 1999 383 390
59. D. Prager, H.L. Li, and S. Asa Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant Proc Natl Acad Sci USA 91 1994 2181 2185
60. J.M. Chan, M.J. Stampfer, and E. Giovannucci Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study Science 279 1998 5350 5636
61. A. Wolk, C.S. Mantzoros, and S.O. Andersson Insulin-like growth factor-I and prostate cancer risk: a population-based case-control study J Natl Cancer Inst 90 12 1998 911 915
62. P. Stattin, A. Bylund, and S. Rinaldi Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study J Natl Cancer Inst 92 23 2000 1910 1917
63. B. Djavan, B. Bursa, and C. Seitz Insulin-like growth factor-I, IGF-I density, and IGF-I/PSA ratio for prostate cancer detection Urology 54 4 1999 603 606
64. L. Li, H. Yu, and F. Schumacher Relation of serum insulin-like growth factor-I and IGF binding protein-3 to risk of prostate cancer (United States) Cancer Causes Control 14 8 2003 721 726
65. A.G. Renehan, M. Zwahlen, and C. Minder Insulin-like growth factor-I, IGF-binding protein-3 and cancer risk: systematic review and meta-regression analysis Lancet 363 9418 2004 1346 1353
66. K. Woodson, J.A. Tangrea, and M. Pollak Serum insulin-like growth factor-I: tumour marker or etiologic factor? A prospective study of prostate cancer among Finnish men Cancer Res 63 14 2003 3991 3994
67. Y. Aksoy, H. Aksoy, and E. Bakan Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia Urol Int 72 1 2004 62 65
68. A.P. Chokkalingam, M. Pollak, and C.M. Fillmore Insulin-like growth factors and prostate cancer: a population-based case-control study in China Cancer Epidemiol Biomarkers Prev 10 5 2001 421 427
69. L.B. Signorello, and H. Adami Prostate cancer H. Adami D. Hunter D. Trichopoulos Textbook of cancer epidemiology 2002 Oxford University Press New York 400 419
70. J.E. Dunn Cancer epidemiology in populations of the United States - with emphasis on Hawaii and California - and Japan Cancer Res 35 11 Pt. 2 1975 3240 3245
71. S.J. Santner, B. Albertson, and G.Y. Zhang Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects J Clin Endocrinol Metab 83 6 1998 2104 2109
72. L.S. Cook, M. Goldoft, and S.M. Schwartz Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants J Urol 161 1 1999 151 155
73. J. Trachtenberg, L.L. Hicks, and P.C. Walsh Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia J Clin Invest 65 5 1980 1051 1059
74. S.O. Andersson, A. Wolk, and R. Bergstrom Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers J Natl Cancer Inst 89 5 1997 385 389
75. C. Rodriguez, A.V. Patel, and E.E. Calle Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States Cancer Epidemiol Biomarkers Prev 10 4 2001 345 353
76. A.W. Hsing, J. Deng, and I.A. Sesterhenn Body size and prostate cancer: a population-based case-control study in China Cancer Epidemiol Biomarkers Prev 9 12 2000 1335 1341
77. E. Giovannucci, E.B. Rimm, and Y. Liu Body mass index and risk of prostate cancer in U.S. health professionals J Natl Cancer Inst 95 16 2003 1240 1244
78. J.S. Hubbard, S. Rohrmann, and P.K. Landis Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging Urology 63 2 2004 253 258
79. F. Jonsson, A. Wolk, and N.L. Pedersen Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry Int J Cancer 106 4 2003 594 599
80. M.A. Howell Factor analysis of international cancer mortality data and per capita food consumption Br J Cancer 29 1974 328 336
81. B. Armstrong, and R. Doll Environmental factors and cancer incidence and mortality in different countries, with special references to dietary practices Int J Cancer 15 1975 617 631
82. L.N. Kolonel, J.H. Hankin, and J. Lee Nutrient intakes in relation to cancer incidence in Hawaii Br J Cancer 44 1981 332 339
83. D.P. Rose, A.P. Boyar, and E.L. Wynder International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption Cancer 58 11 1986 2363 2371
84. E. Giovannucci, E.B. Rimm, and G.A. Colditz A prospective study of dietary fat and risk of prostate cancer J Natl Cancer Inst 85 19 1993 1571 1579
85. P.C. Dagnelie, A.G. Schuurman, and R.A. Goldbohm Diet, anthropomometric measures and prostate cancer risk: a review of prospective cohort and intervention studies BJU Int 93 8 2004 1139 1150
86. A.S. Whittemore, L.N. Kolonel, and A.H. Wu Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada J Natl Cancer Inst 87 9 1995 652 661
87. M.M. Lee, R.T. Wang, and A.W. Hsing Case-control study of diet and prostate cancer in China Cancer Causes Control 9 6 1998 545 552
88. T. Sonoda, Y. Nagata, and M. Mori A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet Cancer Sci 95 3 2004 238 242
89. K. Augustsson, D.S. Michaud, and E.B. Rimm A prospective study of intake of fish and marine fatty acids and prostate cancer Cancer Epidemiol Biomarkers Prev 12 1 2003 64 67
90. A.E. Norrish, C.M. Skeaff, and G.L. Arribas Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study Br J Cancer 81 7 1999 1238 1242
91. L.N. Kolonel, A.M.Y. Nomura, and R.V. Cooney Dietary fat and prostate cancer: current status J Natl Cancer Inst 91 5 1999 414 428
92. M.M. Lee, S.L. Gomez, and J.S. Chang Soy and isoflavone consumption in relation to prostate cancer risk in China Cancer Epidemiol Biomarkers Prev 12 7 2003 665 668
93. B.K. Jacobsen, S.F. Knutsen, and G.E. Fraser Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States) Cancer Causes Control 9 6 1998 553 557
94. M. Onozawa, K. Fukuda, and M. Ohtani Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP Jpn J Clin Oncol 28 6 1998 360 363
95. C. Nagata, N. Takatsuka, and H. Shimizu Effect of soymilk consumption on serum estrogen and androgen concentrations in Japanese men Cancer Epidemiol Biomarkers Prev 10 3 2001 179 184
96. M.A. Yi, H.M. Son, and J.S. Lee Regulation of male sex hormone levels by soy isoflavones in rats Nutr Cancer 42 2 2002 206 210
97. G.-Y. Yang, J. Liao, and K. Kim Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols Carcinogenesis 19 1998 611 616
98. K. Hastak, S. Gupta, and N. Ahmad Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells Oncogene 22 31 2003 4851 4859
99. L. Jian, L.P. Xie, and A.H. Lee Protective effect of green tea against prostate cancer: a case-control study in Southeast China Int J Cancer 108 1 2004 130 135
100. Lycopene - a monograph. Alternative Med Rev 2003, 8(3), 336-342
101. W. Stahl, and H. Sies Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans J Nutr 122 1992 2161 2166
102. P.H. Gann, J. Ma, and E. Giovannucci Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis Cancer Res 59 6 1999 1225 1230
103. C.W. Binns, L.J. LJ, and A.H. Lee The relationship between dietary carotenoids and prostate cancer risk in Southeast Chinese men Asia Pac J Clin Nutr 13 Suppl. 2004 S117
104. M. Etminan, B. Takkouche, and F. Caamano-Isorna The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies Cancer Epidemiol Biomarkers Prev 13 3 2004 340 345
105. W.C. Willett, B.F. Polk, and J.S. Morris Prediagnostic serum selenium and risk of cancer Lancet 2 8342 1983 130 134
106. T.J. Hartman, D. Albanes, and P. Pietinen The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study Cancer Epidemiol Biomarkers Prev 7 4 1998 335 340
107. K.J. Helzlsouer, H.Y. Huang, and A.J. Alberg Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer J Natl Cancer Inst 92 24 2000 2018 2023
108. P.A. van den Brandt, M.P. Zeegers, and P. Bode Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study Cancer Epidemiol Biomarkers Prev 12 9 2003 866 871
109. H. Li, M.J. Stampfer, and E.L. Giovannucci A prospective study of plasma selenium levels and prostate cancer risk J Natl Cancer Inst 96 9 2004 696 703
110. T.M. Vogt, R.G. Ziegler, and B.I. Graubard Serum selenium and risk of prostate cancer in US blacks and whites Int J Cancer 103 5 2003 664 670
111. A.M. Nomura, J. Lee, and G.N. Stemmermann Serum selenium and subsequent risk of prostate cancer Cancer Epidemiol Biomarkers Prev 9 9 2000 883 887
112. T.J. Hartman, D. Albanes, and P. Peitinen The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene prevention study Cancer Epidemiol Biomarkers Prev 7 1998 335 340
113. J.M. Chan, M.J. Stampfer, and J. Ma Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in United States Cancer Epidemiol Biomarkers Prev 8 1999 893 899
114. J. Virtamo, P. Pietinen, and J.K. Huttunen ATBC study group. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up JAMA 290 4 2003 476 485
115. E.A. Klein, I.M. Thompson, and S.M. Lippman SELECT: the next prostate cancer prevention trial. Selenium and vitamin E cancer prevention trial J Urol 166 4 2001 1311 1315